"Throughout his career at Stiefel Laboratories, Jeff has impressed us with his energy, enthusiasm and vast knowledge of the pharmaceutical industry," Stiefel said. "He was an instrumental part of the recent Connetics acquisition, spending several months living in Palo Alto, Calif. and serving as the on-site integration leader. His management skills have contributed to the organization's growth and success internationally and we know he will be a valuable addition to the board."
The Stiefel Laboratories board of directors also includes: William D. (Bill) Humphries, chief commercial officer; Richard MacKay, president, Stiefel Canada, Inc. and vice chairman of the board; Gabriel McGlynn, senior vice president of EURASIA; Brent Stiefel, executive vice president, global corporate development and product portfolio; Catherine Stiefel, certified public accountant, mergers & acquisitions; and Todd Stiefel, executive vice president, global strategy.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is the
world's largest independent pharmaceutical company specializing in
dermatology. The company manufactures and markets a variety of prescription
and non-prescription dermatological products. Some of the newest and best-
known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl
peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R)
(betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol
propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%;
Soriatane(R) (acitretin) capsules; Verdeso(TM) (desonide) Foam, 0.05%;
Brevoxyl(R) Creamy Wash (benzoyl
|SOURCE Stiefel Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved